Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H2 2016

Choose Licence

 

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H2 2016 Summary Global Markets Directs, Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H2 2016?, provides in depth analysis on Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted pipeline therapeutics. The report provides comprehensive information on the Human Cytomegalovirus Envelope Glycoprotein B (gB), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics development and features dormant and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Human Cytomegalovirus Envelope Glycoprotein B (gB) - The report reviews Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics and enlists all their major and minor projects - The report assesses Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Human Cytomegalovirus Envelope Glycoprotein B (gB) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Human Cytomegalovirus Envelope Glycoprotein B (gB) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 

Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Human Cytomegalovirus Envelope Glycoprotein B (gB) Overview 6 Therapeutics Development 7 Human Cytomegalovirus Envelope Glycoprotein B (gB) - Products under Development by Stage of Development 7 Human Cytomegalovirus Envelope Glycoprotein B (gB) - Products under Development by Therapy Area 8 Human Cytomegalovirus Envelope Glycoprotein B (gB) - Products under Development by Indication 9 Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Human Cytomegalovirus Envelope Glycoprotein B (gB) - Products under Development by Companies 12 Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics Assessment 14 Assessment by Monotherapy/Combination Products 14 Assessment by Mechanism of Action 15 Assessment by Route of Administration 16 Assessment by Molecule Type 17 Human Cytomegalovirus Envelope Glycoprotein B (gB) - Companies Involved in Therapeutics Development 19 Astellas Pharma Inc. 19 Trellis Bioscience, Inc. 20 Vakzine Projekt Management GmbH 21 VBI Vaccines Inc 22 Vical Incorporated 23 Human Cytomegalovirus Envelope Glycoprotein B (gB) - Drug Profiles 24 ASP-0113 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 CyMVectin - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 TRL-345 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 VBI-1501A - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 VBI-1901 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 VPM-2001 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Human Cytomegalovirus Envelope Glycoprotein B (gB) - Dormant Projects 35 Human Cytomegalovirus Envelope Glycoprotein B (gB) - Featured News & Press Releases 36 Aug 22, 2016: VBI Vaccines to Continue Enrolling Participants in the Phase I Trial of its Preventative Cytomegalovirus Vaccine Candidate Following Successful Data Safety Monitoring Board Review 36 Jun 23, 2016: VBI Vaccines Begins Enrolling Patients in a Phase I Trial of its Preventative Cytomegalovirus Vaccine Candidate 36 Jun 16, 2016: VBI Vaccines Announces Medulloblastoma Immunotherapy Program 37 Mar 29, 2016: VBI To Present At The World Vaccine Congress Washington 38 Mar 07, 2016: VBI Vaccines Presents New Data Supporting its Glioblastoma Immunotherapy Program at the Keystone Symposia Cancer Vaccines Conference 38 Nov 20, 2015: VBI Vaccines Presents Update and New Data Supporting its Glioblastoma Immunotherapy Program at the ESMO Symposium on Immuno-Oncology 40 Nov 06, 2015: VBI Vaccines to Present Update and New Data Supporting its CMV Vaccine Program at the World Vaccine Congress Europe 41 Aug 26, 2015: VBI Vaccines to Provide an Update on its CMV Vaccine Program at the Tenth Annual IMVACS Summit 42 May 21, 2015: Vical Announces Completion of Enrollment in Phase 2 Clinical Trial of Investigational CMV Vaccine in Kidney Transplant Recipients 42 Apr 21, 2015: Vical Announces Presentation of Preclinical Data for Congenital CMV DNA Vaccine at International Conference 43 Apr 09, 2015: VBI Vaccines Announces New Data Supporting the Manufacture of Its Prophylactic CMV Vaccine Candidate 43 Nov 24, 2014: VBI To Present At The LD Micro Conference 44 Sep 15, 2014: New Data Supporting VBI's Prophylactic Cytomegalovirus (CMV) Vaccine Candidate (VBI-1501A) Presented at the 54th ICAAC Conference in Washington, D.C. 44 Mar 27, 2014: VBI Begins GMP Tech Transfer to Paragon Bioservices 45 Dec 10, 2013: Astellas and Vical Announce Initiation of Phase 2 Trial of ASP0113, a Cytomegalovirus Vaccine, in Solid Organ Transplant Recipients 45 Appendix 46 Methodology 46 Coverage 46 Secondary Research 46 Primary Research 46 Expert Panel Validation 46 Contact Us 46 Disclaimer 47

List of Tables Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Indication, H2 2016 9 Comparative Analysis by Late Stage Development, H2 2016 10 Comparative Analysis by Early Stage Products, H2 2016 11 Number of Products under Development by Companies, H2 2016 12 Products under Development by Companies, H2 2016 13 Assessment by Monotherapy/Combination Products, H2 2016 14 Number of Products by Stage and Mechanism of Action, H2 2016 15 Number of Products by Stage and Route of Administration, H2 2016 16 Number of Products by Stage and Molecule Type, H2 2016 18 Pipeline by Astellas Pharma Inc., H2 2016 19 Pipeline by Trellis Bioscience, Inc., H2 2016 20 Pipeline by Vakzine Projekt Management GmbH, H2 2016 21 Pipeline by VBI Vaccines Inc, H2 2016 22 Pipeline by Vical Incorporated, H2 2016 23 Dormant Projects, H2 2016 35


Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:

Other Reports by Global Markets Direct

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2017

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2017 Summary Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 14 molecules. Out of which approximately 10 molecules are developed by companies and remaining b...

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017 Summary According to the recently published report 'Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017'; Transthyretin (ATTR or Prealbumin or TBP...

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2017

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2017 Summary Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Complement component 5 is a protein...

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2017

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2017 Summary Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) pipeline Target constitutes close to 7 molecules. Out of which approximat...

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H2 2017

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H2 2017 Summary According to the re...

New Pharmaceuticals and Healthcare Reports